Overview
Carcinoma of the glottis, a subtype of laryngeal cancer, primarily affects the true vocal cords and is predominantly squamous cell in origin. This condition is clinically significant due to its impact on voice function and potential for locoregional spread. It predominantly affects middle-aged to elderly individuals, with a slight male predominance. Early detection and appropriate management are crucial as they significantly influence survival rates and quality of life post-treatment. Understanding the nuances of treatment approaches, including radiotherapy and surgical interventions, is essential for optimizing patient outcomes in day-to-day clinical practice 127.Pathophysiology
The pathophysiology of glottis carcinoma typically begins with genetic mutations that lead to uncontrolled proliferation of epithelial cells lining the vocal cords. Chronic irritation from smoking, alcohol consumption, and occupational exposures often plays a pivotal role in initiating these genetic alterations 1. At the molecular level, dysregulation of oncogenes and tumor suppressor genes, such as p53 and Rb, contributes to cellular transformation 1. Cellular changes manifest as dysplastic changes progressing to invasive carcinoma, characterized by loss of cell polarity, increased mitotic activity, and invasion into the underlying tissues. These processes disrupt normal laryngeal function, leading to symptoms like hoarseness and airway obstruction 17.Epidemiology
Glottis carcinoma exhibits an incidence of approximately 10-20 cases per 100,000 individuals annually, with a slight male preponderance and a median age at diagnosis around 60 years 12. Geographic variations exist, with higher incidence rates reported in regions with significant tobacco use and occupational exposures to carcinogens 1. Over time, there has been a trend towards earlier detection due to improved diagnostic techniques and increased awareness, leading to better survival rates, particularly in early-stage disease 2. However, socioeconomic factors and access to healthcare significantly influence both incidence and outcomes 1.Clinical Presentation
Patients with glottis carcinoma often present with persistent hoarseness, which is the hallmark symptom, often lasting more than three weeks 15. Other common symptoms include throat pain, dysphagia, and in advanced cases, airway obstruction. Red-flag features include unexplained weight loss, neck mass, and hemoptysis, which necessitate urgent evaluation for potential metastasis or complications 17. Voice changes can be subtle initially, making thorough laryngoscopic examination crucial for early detection 5.Diagnosis
The diagnostic approach for glottis carcinoma involves a combination of clinical evaluation and imaging studies, culminating in histopathological confirmation. Key steps include:Clinical Evaluation: Detailed history focusing on voice changes, smoking history, and occupational exposures.
Laryngoscopy: Essential for visualizing the vocal cords; endolaryngoscopy with biopsy is definitive 15.
Imaging: CT or MRI to assess local extent and rule out metastasis 1.
Biopsy: Histopathological examination confirms the diagnosis; grading based on TNM staging system 12.Specific Criteria and Tests:
Endolaryngoscopy with Biopsy: Required for definitive diagnosis.
Histopathology: Confirmation of squamous cell carcinoma; grading based on depth of invasion (T1-T4).
Imaging: CT/MRI for staging (N0/N+, M0/M1).
Differential Diagnosis:
- Vocal Cord Nodules/Polyps: Typically unilateral, less invasive on laryngoscopy.
- Laryngitis: Usually reversible with voice rest; lacks malignant features on biopsy.
- Reinke’s Edema: Presents with bilateral swelling, no malignant cells on histopathology 15.Management
Primary Treatment Approaches
#### Radiotherapy
Intensity-Modulated Radiotherapy (IMRT): Carotid-sparing IMRT aims to minimize long-term carotid toxicity while ensuring adequate coverage of the glottis.
- Target Volumes:
- GTV: Defined based on endoscopic and imaging findings.
- CTV: Typically includes vocal cords, arytenoids, and subglottis (0.3-0.5 cm margin).
- PTV: Expanded from CTV by 1-2 cm, tailored to avoid carotid arteries.
- Dose Constraints:
- Carotid Arteries: Maximum dose < 50 Gy (3 studies reported constraints) 1.
- Spinal Cord: Maximum dose < 45 Gy (reported in some studies) 1.
- Prescribed Dose: Commonly 63 Gy in 28 fractions 118.
- Contraindications: Severe comorbidities affecting tolerance to radiation 1.#### Surgical Interventions
Endoscopic Laser Cordectomy: Suitable for early-stage disease, preserving voice quality.
- Types: Type III, IV, and Va cordectomies based on extent of resection.
- Post-Operative Voice Assessment: Utilize GRBAS scale and acoustic analysis for evaluation 34.
- Complications: Irregular vocal fold function (13% rate observed) 7.Second-Line and Refractory Management
Salvage Surgery: For local recurrence post-RT, with caution due to potential complications (29% complication rate noted) 8.
Chemotherapy: Rarely used as primary but considered in metastatic disease or in combination with RT for advanced stages 1.Complications
Acute Complications
Radiation Esophagitis: Common in RT, managed with symptom control and hydration.
Laryngeal Edema: Managed with corticosteroids and supportive care 8.Long-Term Complications
Voice Dysfunction: Persistent hoarseness, requiring speech therapy.
Carotid Artery Injury: Potential stroke risk with non-carotid-sparing RT; monitored with imaging follow-ups 1.
Secondary Malignancies: Risk increases with higher radiation doses; long-term surveillance recommended 1.Prognosis & Follow-Up
Prognosis: Excellent for early-stage disease (T1-T2), with 5-year survival rates exceeding 80% 27.
Prognostic Indicators: Tumor stage, nodal involvement, and patient performance status.
Follow-Up Intervals: Regular laryngoscopy and imaging every 6-12 months for the first few years post-treatment, tapering off based on response and recurrence risk 12.Special Populations
Elderly Patients
Considerations: Higher risk of comorbidities; individualized treatment plans focusing on quality of life 1.
Pediatrics
Rarity: Extremely rare; multidisciplinary approach required for diagnosis and management 1.
Comorbidities
Impact: Significant comorbidities may influence treatment choice, favoring less invasive options like RT over surgery 1.Key Recommendations
Primary Treatment with IMRT or Laser Cordectomy: For early-stage glottis carcinoma, prioritize carotid-sparing IMRT or endoscopic laser cordectomy to preserve voice quality and minimize long-term complications (Evidence: Strong) 134.
Target Volume Definition: Clearly delineate GTV, CTV, and PTV, ensuring adequate coverage while sparing critical structures like the carotid arteries (Evidence: Moderate) 1.
Dose Constraints for Carotid Arteries: Limit maximum dose to carotid arteries to < 50 Gy to reduce stroke risk (Evidence: Moderate) 1.
Regular Post-Treatment Monitoring: Implement laryngoscopy and imaging follow-ups every 6-12 months for early detection of recurrence (Evidence: Moderate) 12.
Voice Assessment Post-Treatment: Use GRBAS scale and acoustic analysis to evaluate and manage voice dysfunction (Evidence: Moderate) 34.
Consider Patient-Specific Factors: Tailor treatment based on age, comorbidities, and performance status (Evidence: Expert opinion) 1.
Salvage Surgery for Recurrence: Reserve for carefully selected cases due to potential complications (Evidence: Moderate) 8.
Avoid Over-Treatment in Early Stages: Focus on organ preservation strategies to enhance quality of life (Evidence: Moderate) 27.
Educate Patients on Self-Examination: Provide voice self-examination cards to monitor for recurrence symptoms (Evidence: Expert opinion) 2.
Multidisciplinary Team Approach: Involve ENT surgeons, radiation oncologists, and speech therapists for comprehensive care (Evidence: Expert opinion) 1.References
1 Gujral DM, Long M, Roe JW, Harrington KJ, Nutting CM. Standardisation of Target Volume Delineation for Carotid-sparing Intensity-modulated Radiotherapy in Early Glottis Cancer. Clinical oncology (Royal College of Radiologists (Great Britain)) 2017. link
2 Lois-Ortega Y, García-Curdi F, Vallés-Varela H, Muniesa-Del Campo A. Survival study in early stages of glottis cancer, stratified by treatment. Acta oto-laryngologica 2022. link
3 Kosztyła-Hojna B, Łuczaj J, Berger G, Duchnowska E, Zdrojkowski M, Łobaczuk-Sitnik A et al.. Perceptual and acoustic voice analysis in patients with glottis cancer after endoscopic laser cordectomy. Otolaryngologia polska = The Polish otolaryngology 2020. link
4 Czecior E, Orecka B, Pawlas P, Mrówka-Kata K, Namysłowski G, Składowski K et al.. Comparative assessment of the voice in patients treated for early glottis cancer by laser cordectomy or radiotherapy. Otolaryngologia polska = The Polish otolaryngology 2012. link
5 Vukasinović M, Djukić V, Stanković P, Krejović-Trivić S, Milovanović J, Mikić A et al.. Nonvibrating segment predicting glottis carcinoma. Acta chirurgica Iugoslavica 2009. link
6 Matassini L, Manfredi C. Software corrections of vocal disorders. Computer methods and programs in biomedicine 2002. link00161-4)
7 Modrzejewski M, Olszewski E, Strek P, Wszołek W, Zielińska J. Effectiveness of classical chordectomy in the treatment of cancer of the glottis. Auris, nasus, larynx 1998. link10028-1)
8 Randall ME, Springer DJ, Raben M. T1-T2 carcinoma of the glottis: relative hypofractionation. Radiology 1991. link